Q1 2022 Results
Company overview
Financial performance
CRM
Immunology
Financial review
Neuroscience
2022 priorities
Appendix
References
Innovation: Pipeline overview
Innovation: Clinical trials
Abbreviations
Ophthalmology
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
canakinumab - IL-1beta inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
Target Patients
NCT03447769 CANOPY-A (CACZ885T2301)
Adjuvant NSCLC
Phase 3
1500
Disease free survival (primary), overall survival (key secondary)
Canakinumab 200mg q3w sc for 18 cycles
Placebo q3w sc for 18 cycles
Patients with:
High-risk NSCLC (AJCC/UICC v.8 stage II-IIIA and IIIB (T>5cm N2)) after complete
resection and standard of care adjuvant cisplatin-based chemotherapy
All histologies
Read-out Milestone(s)
2022
Publication
TBD
91 Investor Relations | Q1 2022 Results
1 NOVARTIS | Reimagining MedicineView entire presentation